310 related articles for article (PubMed ID: 9541154)
1. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
Rudolph RL; Fabre LF; Feighner JP; Rickels K; Entsuah R; Derivan AT
J Clin Psychiatry; 1998 Mar; 59(3):116-22. PubMed ID: 9541154
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
Thase ME
J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
4. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
Khan A; Upton GV; Rudolph RL; Entsuah R; Leventer SM
J Clin Psychopharmacol; 1998 Feb; 18(1):19-25. PubMed ID: 9472838
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
Rudolph RL; Feiger AD
J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
[TBL] [Abstract][Full Text] [Related]
6. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
Silverstone PH; Ravindran A
J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.
Mehtonen OP; Søgaard J; Roponen P; Behnke K
J Clin Psychiatry; 2000 Feb; 61(2):95-100. PubMed ID: 10732656
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR; DuPont RL; Hedges D; Haskins JT
J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
10. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.
Guelfi JD; Ansseau M; Timmerman L; Kørsgaard S;
J Clin Psychopharmacol; 2001 Aug; 21(4):425-31. PubMed ID: 11476127
[TBL] [Abstract][Full Text] [Related]
11. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
Cunningham LA
Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Costa e Silva J
J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.
Ballús C; Quiros G; De Flores T; de la Torre J; Palao D; Rojo L; Gutiérrez M; Casais L; Riesgo Y
Int Clin Psychopharmacol; 2000 Jan; 15(1):43-8. PubMed ID: 10836286
[TBL] [Abstract][Full Text] [Related]
14. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
Feighner JP; Entsuah AR; McPherson MK
J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
[TBL] [Abstract][Full Text] [Related]
16. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
[TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression.
Luthringer R; Toussaint M; Schaltenbrand N; Bailey P; Danjou PH; Hackett D; Guichoux JY; Macher JP
Psychopharmacol Bull; 1996; 32(4):637-46. PubMed ID: 8993085
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.
de Montigny C; Silverstone PH; Debonnel G; Blier P; Bakish D
J Clin Psychopharmacol; 1999 Oct; 19(5):401-6. PubMed ID: 10505581
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.
Amsterdam J
J Clin Psychopharmacol; 1998 Oct; 18(5):414-7. PubMed ID: 9790160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
